The cBioPortal database revealed that the highest incidence of gene alterations in MRPL13 is in ovarian cancer, while it is also amplified in the majority of pan-cancer patients, including those with breast cancer, esophageal cancer, liver cancer, uterine cancer, pancreatic cancer, gastric adenocarcinoma, prostate cancer, head and neck squamous cell carcinoma, bladder cancer, and lung adenocarcinoma. The gene discussed is MRPL13; the disease is familial pancreatic carcinoma.